Nexalin Technology, Inc. - NXL

SEC Filings Our NXL Tweets

About Gravity Analytica

Recent News

12.03.2025 - Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
12.02.2025 - Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4
11.18.2025 - Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity
11.13.2025 - Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel
11.05.2025 - Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia
10.30.2025 - Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel
10.21.2025 - Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies
10.13.2025 - Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer’s and Traumatic Brain Injury Programs
10.10.2025 - Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit
09.25.2025 - Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology

Recent Filings